Your browser doesn't support javascript.
loading
Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy.
Halfdanarson, Thorvardur R; Mallak, Nadine; Paulson, Scott; Chandrasekharan, Chandrikha; Natwa, Mona; Kendi, Ayse Tuba; Kennecke, Hagen F.
Afiliação
  • Halfdanarson TR; Mayo Clinic, Rochester, MN 55905, USA.
  • Mallak N; Division of Molecular Imaging and Therapy, Oregon Health and Science University, Portland, OR 97239, USA.
  • Paulson S; Texas Oncology, Dallas, TX 75230, USA.
  • Chandrasekharan C; College of Medicine, University of Iowa Carver, Iowa City, IA 52242, USA.
  • Natwa M; Langone Health, New York University, New York, NY 10016, USA.
  • Kendi AT; Mayo Clinic, Rochester, MN 55905, USA.
  • Kennecke HF; Providence Cancer Institute Franz Clinic, Portland, OR 97213, USA.
Cancers (Basel) ; 15(19)2023 Oct 02.
Article em En | MEDLINE | ID: mdl-37835530
ABSTRACT
Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos